# Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors

Source: https://onco.cc/trials/nct07146672/  
OnCo record `nct07146672` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Super DC Vaccine in advanced solid tumours, run by Shanghai Cell Therapy Group Co.,Ltd, now recruiting.

## Summary

Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors is a phase 1/2 interventional study registered as NCT07146672 by Shanghai Cell Therapy Group Co.,Ltd, with 12 participants planned, started 2025-07-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: Super DC Vaccine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07146672
- Phase: 1/2
- Setting: Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
- Sponsor: Shanghai Cell Therapy Group Co.,Ltd
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07146672: https://clinicaltrials.gov/study/NCT07146672

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07146672.json